Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine), an Antimetabolite That Poisons Topoisomerase I

Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine), an Antimetabolite That Poisons Topoisomerase I

Laboratory of Molecular Pharmacology, Division of Basic Sciences, NCI, National Institutes of Health, Bethesda, Maryland [P. P., C. G., G. K., Y. U., Y. M., Y. P.]; Unité d’oncologie médicale, Hôpital Cochin, Paris, France [F. G.]; Cancer Research Division, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana [L. W. H.]; Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, North-Carolina [W. H. G.]; Core DNA Synthesis Facility, University of Calgary, Calgary, Alberta, Canada [S. Y., R. T. P.]

Abstract

Purpose: Gemcitabine-containing regimens are among standard therapies for the treatment of advanced non-small cell lung,pancreatic, or bladder cancers. Gemcitabine is a nucleoside analogue and its cytotoxicity is correlated with incorporation into genomic DNA and concomitant inhibition of DNA synthesis. However, it is still unclear by which mechanism(s) gemcitabine incorporation leads to cell death.

Experimental Design: We used purified oligodeoxynucleotides to study the effects of gemcitabine incorporation on topoisomerase I (top1) activity and tested the role of top1 poisoning in gemcitabine-induced cytotoxicity in cancer cells.

Results: We found that top1-mediated DNA cleavage was enhanced when gemcitabine was incorporated immediately 3′ from a top1 cleavage site on the nonscissile strand. This position-specific enhancement was attributable to an increased DNA cleavage by top1 and was likely to have resulted from a combination of gemcitabine-induced conformational and electrostatic effects. Gemcitabine also enhanced camptothecin-induced cleavage complexes. We also detected top1 cleavage complexes in human leukemia CEM cells treated with gemcitabine and a 5-fold resistance of P388/CPT45 top1-deficient cells to gemcitabine, indicating that poisoning of top1 can contribute to the antitumor activity of gemcitabine.

Conclusions: The present results extend our recent finding that incorporation of 1-β-d-arabinofuranosylcytosine into DNA can induce top1 cleavage complexes [P. Pourquier et al. Proc. Natl. Acad. Sci. USA, 97: 1885–1890, 2000]. The enhancement of camptothecin-induced top1 cleavage complexes may, at least in part, contribute to the synergistic or additive effects of gemcitabine in combination with topotecan and irinotecan in human breast or lung cancer cells.

Footnotes

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
↵1 Present address: Laboratoire de Pharmacologie des Agents Anticancéreux, Institut Bergonié, Bordeaux, France.
↵2 Present address: First Department of Medicine, Fukui Medical University, Fukui, Japan.
↵3 To whom requests for reprints should be addressed, at Building 37, Room 5068, NIH, Bethesda, MD 20892-4255. Phone: (301) 496-5944; Fax: (301) 402-0752; E-mail: pommier{at}nih.gov
↵4 The abbreviations used are: ara-C, 1-β-d-arabinofuranosylcytosine; top1: DNA topoisomerase I; CPT, camptothecin; NMR, nuclear magnetic resonance; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Gem, gemcitabine; ICE, in vivo complex of enzyme.
- Accepted May 14, 1902.
- Received December 31, 1902.
- Revision received May 8, 1902.